Quote | F-star Therapeutics Inc Com (NASDAQ:FSTX)
Last: | $7.12 |
---|---|
Change Percent: | 0.14% |
Open: | $7.11 |
Close: | $7.12 |
High: | $7.12 |
Low: | $7.11 |
Volume: | 987,072 |
Last Trade Date Time: | 03/08/2023 03:00:00 am |
News | F-star Therapeutics Inc Com (NASDAQ:FSTX)
2023-04-17 17:44:40 ET Summary This month I had 5 transactions. New forward dividends are approximately $1,121. Next month I will look at Morgan Stanley, Prudential Financial, CVS Health, and Brookfield Asset Management. March was a bad month for my portfolio, as it ...
2023-03-13 00:55:00 ET Summary Sino Biopharm was approved to close its $161 million all-cash acquisition of F-star, a Cambridge, UK company that develops bispecific antibodies. Harbour BioMed announced positive results from a China Phase III trial of its anti-FcRn mAb in patients ...
Message Board Posts | F-star Therapeutics Inc Com (NASDAQ:FSTX)
Subject | By | Source | When |
---|---|---|---|
znewcar1: $FSTX 25% v2,0M c5.44 f21,981M H5.72 ML4.01 YL4.08 gap ne hold | znewcar1 | investorshangout | 12/22/2022 2:16:54 AM |
https://www.sec.gov/Archives/edgar/data/1566373/000119312522309497/d427731dsc14d | DK11 | investorshub | 12/21/2022 4:18:20 PM |
https://www.sec.gov/Archives/edgar/data/1566373/000119312522309497/d427731dsc14d | DK11 | investorshub | 12/21/2022 4:17:04 PM |
https://www.sec.gov/Archives/edgar/data/1566373/000119312522309500/d439272d8k.ht | DK11 | investorshub | 12/21/2022 4:02:52 PM |
invoX Pharma to Acquire F-Star Therapeutics (FSTX) for | subslover | investorshub | 06/23/2022 2:44:57 PM |
News, Short Squeeze, Breakout and More Instantly...
F-star Therapeutics Inc Com Company Name:
FSTX Stock Symbol:
NASDAQ Market:
Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWI...
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”) , a clinical-stage biopharmaceutical company dedicated to developing next-generation immunotherapies to t...
LONDON, Jan. 26, 2023 (GLOBE NEWSWIRE) -- invoX Pharma (“invoX”), a wholly owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK), and F-star Therapeutics, Inc. (“F-star”) (NASDAQ:FSTX), today issued the following statemen...